Study guide

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP)

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP)

Key Takeaways Explain This Topic AI

Hemorrhagic shock resuscitation centers on Damage Control Resuscitation (DCR), avoiding crystalloid overload while enforcing permissive hypotension (target SBP 80–90 mmHg, MAP ~50–60 mmHg) until surgical source control is achieved—EXCEPT in traumatic brain injury (TBI), where target SBP must be ≥ 110 mmHg to maintain adequate cerebral perfusion pressure.

The traditional Lethal Triad of Trauma (Hypothermia, Acidosis, and Coagulopathy) has expanded into the Lethal Diamond with the inclusion of Hypocalcemia (ionized calcium < 0.9–1.1 mmol/L), driven by citrate toxicity from rapid blood product transfusion.

Massive Transfusion Protocol (MTP) utilizes a balanced 1:1:1 blood product ratio (PRBCs : FFP : Platelets) or Low-Titer O Positive/Negative Whole Blood (LTOWB) to restore oxygen-carrying capacity and maintain coagulation factor parity.

Tranexamic Acid (TXA) must be administered as a 1 g IV/IO bolus over 10 minutes within 3 hours of trauma, followed by a 1 g IV infusion over 8 hours, to competitively inhibit hyperfibrinolysis.

Viscoelastic testing (TEG/ROTEM) guides targeted component therapy: prolonged R-time dictates FFP/PCC; low Alpha angle/K-time dictates Cryoprecipitate; decreased MA dictates Platelets/DDAVP; elevated LY30 dictates TXA.

Last updated: July 2026

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP)

Hemorrhagic shock remains the leading cause of preventable death in trauma patients. Modern critical care transport requires a fundamental paradigm shift away from high-volume crystalloid resuscitation toward Damage Control Resuscitation (DCR) , balanced blood product administration, and target-driven hemostatic optimization.

Pathophysiology & Classification of Hemorrhagic Shock

Hemorrhagic shock is a hypovolemic state resulting from rapid intravascular volume depletion, causing tissue hypoperfusion, cellular hypoxia, systemic anaerobic metabolism, and progressive lactic acidosis. The American College of Surgeons Advanced Trauma Life Support (ATLS) categorizes hemorrhage into four distinct physiological classes:

Parameter Class I (Mild) Class II (Moderate) Class III (Severe) Class IV (Life-Threatening)

Blood Loss (mL) < 750 mL < 750 \text{ mL} < 750 mL 750 − 1500 mL 750 - 1500 \text{ mL} 750 − 1500 mL 1500 − 2000 mL 1500 - 2000 \text{ mL} 1500 − 2000 mL > 2000 mL > 2000 \text{ mL} > 2000 mL

Blood Loss (% Volume) < 15 % < 15\% < 15% 15 % − 30 % 15\% - 30\% 15% − 30% 30 % − 40 % 30\% - 40\% 30% − 40% > 40 % > 40\% > 40%

Heart Rate (bpm) < 100 < 100 < 100 100 − 120 100 - 120 100 − 120 120 − 140 120 - 140 120 − 140 > 140 > 140 > 140

  • Systolic Blood Pressure Normal Normal Decreased ( < 90 mmHg < 90 \text{ mmHg} < 90 mmHg ) Severely Decreased
  • Pulse Pressure Normal / Increased Narrowed Narrowed Severely Narrowed
  • Respiratory Rate 14 − 20 14 - 20 14 − 20 20 − 30 20 - 30 20 − 30 30 − 40 30 - 40 30 − 40 > 35 > 35 > 35

Urine Output (mL/hr) > 30 mL/hr > 30 \text{ mL/hr} > 30 mL/hr 20 − 30 mL/hr 20 - 30 \text{ mL/hr} 20 − 30 mL/hr 5 − 15 mL/hr 5 - 15 \text{ mL/hr} 5 − 15 mL/hr Negligible

Mental Status / GCS Slightly Anxious Mildly Anxious Anxious / Confused Confused / Lethargic

Base Deficit 0 to − 2 mEq/L 0 \text{ to } -2 \text{ mEq/L} 0 to − 2 mEq/L − 2 to − 6 mEq/L -2 \text{ to } -6 \text{ mEq/L} − 2 to − 6 mEq/L − 6 to − 10 mEq/L -6 \text{ to } -10 \text{ mEq/L} − 6 to − 10 mEq/L < − 10 mEq/L < -10 \text{ mEq/L} < − 10 mEq/L

The Lethal Triad to the Lethal Diamond of Trauma

Traumatic injury triggers a vicious self-amplifying pathological spiral traditionally known as the Lethal Triad of Trauma , which consists of:

Hypothermia ( < 35 ∘ C < 35^\circ\text{C} < 3 5 ∘ C ) : Impairs the enzymatic function of the coagulation cascade. At core temperatures < 33 ∘ C < 33^\circ\text{C} < 3 3 ∘ C , clotting factor synthesis and platelet aggregation drop by over 50%.

Acidosis ( pH < 7.20 \text{pH} < 7.20 pH < 7.20 ) : Lactic acidosis directly inhibits coagulation factor assembly. The activity of the Factor VIIa/Tissue Factor complex decreases by 50% at a pH of 7.20 and by 90% at a pH of 6.80.

Trauma-Induced Coagulopathy (TIC) : Driven by tissue trauma, shock, consumption of factors, hyperfibrinolysis, and endothelial glycocalyx degradation.

Modern critical care medicine expands this concept to the Lethal Diamond , recognizing Hypocalcemia as the critical fourth pillar. Lethal Diamond = Hypothermia + Acidosis + Coagulopathy + Hypocalcemia \text{Lethal Diamond} = \text{Hypothermia} + \text{Acidosis} + \text{Coagulopathy} + \text{Hypocalcemia} Lethal Diamond = Hypothermia + Acidosis + Coagulopathy + Hypocalcemia

Ionized calcium ( iCa 2 + \text{iCa}^{2+} iCa 2 + ) is Factor IV in the coagulation cascade and is essential for platelet activation, fibrin assembly, and vascular tone. Transfusion of citrate-preserved blood products (PRBCs and FFP) rapidly chelates serum ionized calcium. An iCa 2 + < 0.9 mmol/L \text{iCa}^{2+} < 0.9 \text{ mmol/L} iCa 2 + < 0.9 mmol/L severely impairs cardiac contractility and exacerbates refractory coagulopathic bleeding.

Principles of Damage Control Resuscitation (DCR)

Damage Control Resuscitation prioritizes rapid hemostasis and metabolic stability over normotensive volume restoration prior to definitive surgical intervention.

1. Permissive Hypotension (Hemostatic Resuscitation)

Target Parameters : Maintain Systolic Blood Pressure (SBP) at 80 − 90 mmHg 80 - 90 \text{ mmHg} 80 − 90 mmHg and Mean Arterial Pressure (MAP) at ≈ 50 − 60 mmHg \approx 50 - 60 \text{ mmHg} ≈ 50 − 60 mmHg in patients with active non-compressible torso hemorrhage.

Rationale : Lower hydrostatic pressure prevents "popping the clot" (dislodging fragile initial hemostatic plugs) and limits dilutional displacement of endogenous clotting factors.

CRITICAL EXCEPTION — Traumatic Brain Injury (TBI) : In patients with confirmed or suspected TBI (isolated or concomitant), permissive hypotension is strictly contraindicated . Hypotension ( SBP < 90 mmHg \text{SBP} < 90 \text{ mmHg} SBP < 90 mmHg ) doubles mortality in TBI by compromising Cerebral Perfusion Pressure ( CPP = MAP − ICP \text{CPP} = \text{MAP} - \text{ICP} CPP = MAP − ICP ). Target SBP ≥ 110 mmHg \text{SBP} \ge 110 \text{ mmHg} SBP ≥ 110 mmHg (or MAP ≥ 80 mmHg \text{MAP} \ge 80 \text{ mmHg} MAP ≥ 80 mmHg ) in patients aged 15–49 or 65+, and SBP ≥ 100 mmHg \text{SBP} \ge 100 \text{ mmHg} SBP ≥ 100 mmHg in patients aged 50–64.

2. Elimination of Crystalloid Overload

Large-volume isotonic crystalloids (0.9% Normal Saline or Lactated Ringer's) cause dilutional coagulopathy, hyperchloremic metabolic acidosis (with 0.9% NaCl), tissue edema, and increased mortality. Crystalloid administration should be restricted to minimal boluses only when blood products are unavailable.

Massive Transfusion Protocols (MTP) & Ratios

Massive Transfusion is defined as the administration of ≥ 10 units \ge 10 \text{ units} ≥ 10 units of Packed Red Blood Cells (PRBCs) within 24 hours, ≥ 4 units \ge 4 \text{ units} ≥ 4 units within 1 hour, or the replacement of > 50 % > 50\% > 50% of total blood volume in 3 hours.

Balanced Product Ratios (1:1:1)

Modern MTP mandates a 1:1:1 ratio of blood components: 1 Unit PRBCs : 1 Unit FFP : 1 Unit Platelets \text{1 Unit PRBCs} : \text{1 Unit FFP} : \text{1 Unit Platelets} 1 Unit PRBCs : 1 Unit FFP : 1 Unit Platelets

This ratio reconstructs reconstituted whole blood (yielding a hematocrit of ∼ 29 % \sim 29\% ∼ 29% , platelet count of ∼ 88 , 000 / μ L \sim 88,000/\mu\text{L} ∼ 88 , 000/ μ L , and coagulation factor activity of ∼ 65 % \sim 65\% ∼ 65% ). Low-Titer O Positive/Negative Whole Blood (LTOWB) is increasingly utilized in critical care transport as it delivers unseparated, fully functional red cells, plasma factors, and platelets in a single physiological unit.

Pharmacological Resuscitation & Calcium Protocol

Tranexamic Acid (TXA) : A synthetic lysine analog that competitively inhibits plasminogen activation, blocking fibrinolysis.

Dosing : Administer 1 g 1 \text{ g} 1 g IV/IO bolus over 10 minutes within 3 hours of injury (CRASH-2 trial demonstrated significant reduction in mortality when given < 3 hours < 3 \text{ hours} < 3 hours ; administration > 3 hours > 3 \text{ hours} > 3 hours post-injury increases mortality). Follow with a second 1 g 1 \text{ g} 1 g IV maintenance infusion over 8 hours .

CRASH-3 Trial : Supports TXA utility in mild-to-moderate traumatic brain injury (GCS 9–14) without increasing thromboembolic risk.

Calcium Administration : Administer 1 g 1 \text{ g} 1 g Calcium Chloride (or 3 g 3 \text{ g} 3 g Calcium Gluconate) IV/IO for every 4 units of blood products transfused, titrating to maintain ionized calcium iCa 2 + > 1.1 mmol/L \text{iCa}^{2+} > 1.1 \text{ mmol/L} iCa 2 + > 1.1 mmol/L . Note: Calcium chloride delivers 3x more elemental calcium per gram than calcium gluconate and requires central or secure large-bore IV access.

Thromboelastography (TEG) & ROTEM Interpretation

Viscoelastic assays evaluate the viscoelastic properties of whole blood from initial fibrin formation through clot maturation and lysis, providing real-time point-of-care guidance for targeted transfusions. TEG Tracing Diagram:

  • Split Point (SP)
  • |---| Reaction Time (R-time)
  • |------| K-time
  • |======\ Alpha Angle (α)
  • |=======\================ MAX AMPLITUDE (MA)
  • |========\ |
  • |=========\--------------| LY30 (% Lysis at 30 min)

TEG Parameter Normal Range Clinical Significance & Defect Specific Treatment Target

R-time (Reaction Time) 5 − 10 min 5 - 10 \text{ min} 5 − 10 min Time to initial fibrin clot formation; measures clotting factor levels Fresh Frozen Plasma (FFP) ( 10 − 15 mL/kg 10 - 15 \text{ mL/kg} 10 − 15 mL/kg ) or PCC

K-time 1 − 3 min 1 - 3 \text{ min} 1 − 3 min Time from R-time until clot reaches 20 mm amplitude; measures clot kinetics & fibrinogen Cryoprecipitate ( 10 units 10 \text{ units} 10 units ) or Fibrinogen Concentrate

Alpha Angle ( α \alpha α ) 53 ∘ − 72 ∘ 53^\circ - 72^\circ 5 3 ∘ − 7 2 ∘ Slope of tracing curve; reflects fibrinogen interaction with platelets Cryoprecipitate ( 1 unit per 10 kg 1 \text{ unit per 10 kg} 1 unit per 10 kg )

Max Amplitude (MA) 50 − 70 mm 50 - 70 \text{ mm} 50 − 70 mm Peak dynamic strength of clot; 80% platelet count/function , 20% fibrinogen Platelets ( 1 apheresis unit 1 \text{ apheresis unit} 1 apheresis unit ) ± \pm ± DDAVP ( 0.3 μ g/kg 0.3 \ \mu\text{g/kg} 0.3 μ g/kg )

LY30 0 % − 3 % 0\% - 3\% 0% − 3% Percentage of clot retraction/lysis 30 minutes after MA; measures fibrinolysis Tranexamic Acid (TXA) ( 1 g 1 \text{ g} 1 g IV bolus)

ROTEM Equivalent CT (Clotting Time) CFT (Clot Formation Time) / α-angle MCF (Max Clot Firmness) / ML (Max Lysis)